Sarclisa

In combination w/ pomalidomide & dexamethasone for adult patients w/ relapsed & refractory multiple myeloma who have received at least 2 prior therapies including lenalidomide & a proteasome inhibitor & have demonstrated disease progression on the last therapy; w/ carfilzomib & dexamethasone for adult patients w/ relapsed or refractory multiple myeloma who have received 1-3 prior therapies.

Premed Administer 15-60 min prior to starting Sarclisa infusion. Dexamethasone 40 mg PO or IV (or 20 mg PO or IV for patients ≥75 yr) when administered in combination w/ isatuximab & pomalidomide. Dexamethasone 20 mg (IV on the days of isatuximab &/or carfilzomib infusions, & PO on the other days) when administered in combination w/ isatuximab & carfilzomib. Acetaminophen 650-1,000 mg PO (or equiv). Diphenhydramine 25-50 mg IV or PO [or equiv (eg, cetirizine, promethazine, dexchlorpheniramine)]. IV Adult Recommended dose: 10 mg/kg wkly for cycle 1 (days 1, 8, 15, 22) then every 2 wk for cycle 2 (days 1, 15) & beyond; repeat until disease progression or unacceptable toxicity.

Hypersensitivity.

Targeted Cancer Therapy

L01FC02 - isatuximab ; Belongs to the class of CD38 (Clusters of Differentiation 38) inhibitors. Used in the treatment of cancer.

POM